Granite Point Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Granite Point Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,111	Closed	-$1.01M	–	137
2018 Q3	$1.01M	Buy	+1,111	New	+$733K	0.07%	79
2018 Q2	–	Sell	-366	Closed	-$239K	–	149
2018 Q1	$239K	Buy	+366	New	+$275K	0.02%	97

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Granite Point Capital Management's HTGM Position: Q4 2018 in Review

Granite Point Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2018, closing a stake of 1,111 shares — an estimated $1.01M sold.

Granite Point Capital Management first reported a position in HTGM in Q1 2018 and held it in 2 quarters. The position peaked at $1.01M in Q3 2018. 48 funds tracked by Wall St. Rank hold HTGM as of Q4 2018.

Granite Point Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Granite Point Capital Management sold 1,111 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2018, an estimated $1.01M.
Granite Point Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
Granite Point Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $1.01M in Q3 2018.
48 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2018.

Based on Granite Point Capital Management's 13F filing for Q4 2018, filed 5 Feb 2019.